AstraZeneca has seen three of its drugs approved by the Japanese regulator – a new indication for its cancer drug Lynparza, and two new combination therapies for patients with chronic obstr
AstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing risk of disease progression or death by 69%.